Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes

Standard interventions for glioma include surgery, radiation and chemotherapies but the prognosis for malignant cases such as glioblastoma multiforme remain grim. Even with targeted therapeutic agent, bevacitumab, malignant glioma often develops resistance and recurrence. Thus, developing alternative interventions (therapeutic targets, biomarkers) is urgently required. Bruton's tyrosine kinase (Btk) has been long implicated in B cell malignancies but surprisingly it has recently been shown to also play a tumorigenic role in solid tumors such as ovarian and prostate cancer. Bioinformatics data indicates that Btk is significantly higher in clinical glioma samples as compared to normal brain cells and Btk expression level is associated with stage progression. This prompts us to investigate the potential role of Btk as a therapeutic target for glioma. Here, we demonstrate Btk expression is associated with GBM tumorigenesis. Down-regulation of Btk in GBM cell lines showed a significantly reduced abilities in colony formation, migration and GBM sphere-forming potential. Mechanistically, Btk-silenced cells showed a concomitant reduction in the expression of CD133 and Akt/mTOR signaling. In parallel, Ibrutinib (a Btk inhibitor) treatment led to a similar anti-tumorigenic response. Using xenograft mouse model, tumorigenesis was significantly reduced in Btk-silenced or ibrutinib-treated mice as compared to control counterparts. Finally, our glioma tissue microarray analysis indicated a higher Btk staining in the malignant tumors than less malignant and normal brain tissues. Collectively, Btk may represent a novel therapeutic target for glioma and ibrunitib may be used as an adjuvant treatment for malignant GBM.

[1]  M. Hsiao,et al.  Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448 , 2016, BMC Cancer.

[2]  V. Sukhatme,et al.  Drug repurposing in oncology—patient and health systems opportunities , 2015, Nature Reviews Clinical Oncology.

[3]  T. Jiang,et al.  c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma. , 2015, Brain : a journal of neurology.

[4]  Gang Zhao,et al.  NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. , 2015, Cancer letters.

[5]  S. Mourah,et al.  Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. , 2015, Blood.

[6]  Gang Zhao,et al.  Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo , 2015, Oncotarget.

[7]  N. Gray,et al.  Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells , 2015, Oncotarget.

[8]  K. Blum,et al.  Bruton's tyrosine kinase inhibitors in B‐cell non‐Hodgkin's lymphomas , 2015, Clinical pharmacology and therapeutics.

[9]  E. Aronica,et al.  CD133+ and Nestin+ Glioma Stem-Like Cells Reside Around CD31+ Arterioles in Niches that Express SDF-1α, CXCR4, Osteopontin and Cathepsin K , 2015, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  Esther S. Kim,et al.  Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia , 2015, Drugs.

[11]  P. Fisher,et al.  Astrocyte elevated gene-1 interacts with Akt isoform 2 to control glioma growth, survival, and pathogenesis. , 2014, Cancer research.

[12]  Hunter S. Futch,et al.  Differential Connexin Function Enhances Self-Renewal in Glioblastoma , 2014, Cell reports.

[13]  K. Lam,et al.  Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor , 2014, Cell Death and Disease.

[14]  Atique U. Ahmed,et al.  Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy , 2014, Cell Death and Differentiation.

[15]  C. Beier,et al.  Glioblastoma cancer stem cells--from concept to clinical application. , 2013, Cancer letters.

[16]  P. Ascierto,et al.  NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug , 2012, Journal of Translational Medicine.

[17]  I. Yang,et al.  CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. , 2012, Neurosurgery clinics of North America.

[18]  R. McLendon,et al.  Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. , 2011, Cancer cell.

[19]  Stephan Frank,et al.  MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma. , 2011, Cancer research.

[20]  C. James,et al.  Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging , 2010, Journal of visualized experiments : JoVE.

[21]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[22]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[23]  K. Nishio,et al.  Identification of expressed genes characterizing long-term survival in malignant glioma patients , 2006, Oncogene.

[24]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[25]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[26]  H. Kung,et al.  Signaling network of the Btk family kinases , 2000, Oncogene.

[27]  M. Tan,et al.  Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  H. Friedman,et al.  Temozolomide and treatment of malignant glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  J. Sarkaria,et al.  Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation. , 2016, Neuro-oncology.

[30]  Lei Wei,et al.  Nestin Expression Is Associated with Poor Clinicopathological Features and Prognosis in Glioma Patients: an Association Study and Meta-analysis , 2016, Molecular Neurobiology.